RCS - Oxford Cannabinoid - Oxford Cannabinoid Technologies video with Doceo

Oxford Cannabinoid Technologies HoldingsAnnouncement

26/03/2024 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240326:nRSZ3425Ia&default-theme=true

RNS Number : 3425I  Oxford Cannabinoid Tech.Holdings  26 March 2024

 

Oxford Cannabinoid Technologies Holdings plc (OCT) have launched new video
content with Doceo.

 

OCT is a pharmaceutical company developing prescription cannabinoid medicines
for approval by global regulatory agencies and targeting the US$ multi-billion
pain market. OCT aims to revolutionise drug development by utilising a diverse
range of compounds, including proprietary cannabinoid derivatives, natural
phytocannabinoids, and innovative new chemical entities (NCEs) that target the
endocannabinoid system.

 

Clarissa Sowemimo-Coker, Chief Executive Officer, explains how the company is
developing non-addictive, cannabinoid-based medicines. There is demand for
alternatives from people living with debilitating pain conditions that are
poorly served by current treatments.

 

 

 

For further information on Doceo please visit www.doceo.tv
(https://www.doceo.tv/)  or contact the team on info@doceo.tv
(mailto:info@doceo.tv)

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABGGDXXUDDGSL